Search

Your search keyword '"Salvà, Francesc"' showing total 36 results
Start Over Author "Salvà, Francesc"
36 results on '"Salvà, Francesc"'

1. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

Author

Contreras-Toledo, Débora, Jiménez-Fonseca, Paula, López, Carlos López, Montes, Ana Fernández, López Muñoz, Ana María, Vázquez Rivera, Francisca, Alonso, Vicente, Alcaide, Julia, Salvà, Francesc, Covela Rúa, Marta, Guillot, Mónica, Martín Carnicero, Alfonso, Jimeno Mate, Raquel, Cameselle García, Soledad, Asensio Martínez, Elena, González Astorga, Beatriz, Fernandez-Diaz, Amaya B., González Villaroel, Paula, Virgili Manrique, Anna C., Melián Sosa, Marcos, Alonso, Beatriz, Cousillas Castiñeiras, Antia, Castañón López, Carmen, Aparicio, Jorge, and Carmona-Bayonas, Alberto

Published
2024
Full Text
View/download PDF

3. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy

Author

González, Nadia Saoudi, primary, Marchese, Paola Valeria, additional, Baraibar, Iosune, additional, Ros, Javier, additional, Salvà, Francesc, additional, Rodríguez, Marta, additional, Salvà, Clara, additional, Vaghi, Caterina, additional, Alcaraz, Adriana, additional, García, Ariadna, additional, Tabernero, Josep, additional, and Élez, Elena, additional

Published
2024
Full Text
View/download PDF

9. Impact of the COVID-19 pandemic in the early-onset colorectal cancer

Author

Baraibar, Iosune, primary, García, Ariadna, additional, Salvà, Francesc, additional, Ros, Javier, additional, Saoudi, Nadia, additional, Comas, Raquel, additional, Castillo, Gloria, additional, Sanchis, Mireia, additional, García-Álvarez, Alejandro, additional, Hernando, Jorge, additional, Capdevila, Jaume, additional, Castells, Marta R, additional, Martí, Marc, additional, Landolfi, Stefania, additional, Espín, Eloy, additional, Navalpotro, Begoña, additional, Guevara, Jorge, additional, Dopazo, Cristina, additional, Nuciforo, Paolo, additional, Vivancos, Ana, additional, Tabernero, Josep, additional, and Élez, Elena, additional

Published
2023
Full Text
View/download PDF

10. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy

Author

Élez, Elena, primary, Mulet-Margalef, Núria, additional, Sanso, Miriam, additional, Ruiz-Pace, Fiorella, additional, Mancuso, Francesco M., additional, Comas, Raquel, additional, Ros, Javier, additional, Argilés, Guillem, additional, Martini, Giulia, additional, Sanz-Garcia, Enrique, additional, Baraibar, Iosune, additional, Salvà, Francesc, additional, Noguerido, Alba, additional, Cuadra-Urteaga, Jose Luis, additional, Fasani, Roberta, additional, Garcia, Ariadna, additional, Jimenez, Jose, additional, Aguilar, Susana, additional, Landolfi, Stefania, additional, Hernández-Losa, Javier, additional, Braña, Irene, additional, Nuciforo, Paolo, additional, Dienstmann, Rodrigo, additional, Tabernero, Josep, additional, Salazar, Ramon, additional, and Vivancos, Ana, additional

Published
2022
Full Text
View/download PDF

13. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.

Author

Élez, Elena, Mulet-Margalef, Núria, Sanso, Miriam, Ruiz-Pace, Fiorella, Mancuso, Francesco M., Comas, Raquel, Ros, Javier, Argilés, Guillem, Martini, Giulia, Sanz-Garcia, Enrique, Baraibar, Iosune, Salvà, Francesc, Noguerido, Alba, Cuadra-Urteaga, Jose Luis, Fasani, Roberta, Garcia, Ariadna, Jimenez, Jose, Aguilar, Susana, Landolfi, Stefania, and Hernández-Losa, Javier

Subjects
COLORECTAL cancer, DNA mismatch repair, BIOMARKERS, PROGRAMMED cell death 1 receptors, T cells, MICROSATELLITE repeats, PROGRAMMED death-ligand 1, POLYMERASE chain reaction
Abstract

The search for immunotherapy biomarkers in Microsatellite Instability High/Deficient Mismatch Repair system (MSI-H/dMMR) metastatic colorectal cancer (mCRC) is an unmet need. Sixteen patients with mCRC and MSI-H/dMMR (determined by either immunohistochemistry or polymerase chain reaction) treated with PD-1/PD-L1 inhibitors at our institution were included. According to whether the progression-free survival with PD-1/PD-L1 inhibitors was longer than 6 months or shorter, patients were clustered into the IT-responder group (n: 9 patients) or IT-resistant group (n: 7 patients), respectively. In order to evaluate determinants of benefit with PD-1/PD-L1 inhibitors, we performed multimodal analysis including genomics (through NGS panel tumour-only with 431 genes) and the immune microenvironment (using CD3, CD8, FOXP3 and PD-L1 antibodies). The following mutations were more frequent in IT-resistant compared with IT-responder groups: B2M (4/7 versus 2/9), CTNNB1 (2/7 versus 0/9), and biallelic PTEN (3/7 versus 1/9). Biallelic ARID1A mutations were found exclusively in the IT-responder group (4/9 patients). Tumour mutational burden did not correlate with immunotherapy benefit, neither the rate of indels in homopolymeric regions. Of note, biallelic ARID1A mutated tumours had the highest immune infiltration and PD-L1 scores, contrary to tumours with CTNNB1 mutation. Immune microenvironment analysis showed higher densities of different T cell subpopulations and PD-L1 expression in IT-responders. Misdiagnosis of MSI-H/dMMR inferred by discordances between immunohistochemistry and polymerase chain reaction was only found in the IT-resistant population (3/7 patients). Biallelic ARID1A mutations and Wnt signalling activation through CTNNB1 mutation were associated with high and low T cell immune infiltrates, respectively, and deserve special attention as determinants of response to PD-1/PD-L1 inhibitors. The non-MSI-H phenotype in dMMR is associated with poor benefit to immunotherapy. Our results suggest that mechanisms of resistance to immunotherapy are multi-factorial. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Up-to-date role of aflibercept in the treatment of colorectal cancer

Author

Saoudi Gonzalez, Nadia, primary, Salvà, Francesc, additional, Ros, Javier, additional, Baraibar, Iosune, additional, Marmolejo, David, additional, Valdivia, Augusto, additional, Cuadra-Urteaga, Jose Luis, additional, Mulet, Nuria, additional, Tabernero, Josep, additional, and Élez, Elena, additional

Published
2021
Full Text
View/download PDF

15. EGFR Amplification in Metastatic Colorectal Cancer

Author

Randon, Giovanni, primary, Yaeger, Rona, additional, Hechtman, Jaclyn F, additional, Manca, Paolo, additional, Fucà, Giovanni, additional, Walch, Henry, additional, Lee, Jeeyun, additional, Élez, Elena, additional, Seligmann, Jenny, additional, Mussolin, Benedetta, additional, Pagani, Filippo, additional, Germani, Marco Maria, additional, Ambrosini, Margherita, additional, Rossini, Daniele, additional, Ratti, Margherita, additional, Salvà, Francesc, additional, Richman, Susan D, additional, Wood, Henry, additional, Nanjangud, Gouri, additional, Gloghini, Annunziata, additional, Milione, Massimo, additional, Bardelli, Alberto, additional, de Braud, Filippo, additional, Morano, Federica, additional, Cremolini, Chiara, additional, and Pietrantonio, Filippo, additional

Published
2021
Full Text
View/download PDF

21. The role of pro‐, pre‐ and symbiotics in cancer: A systematic review.

Author

Miarons, Marta, Roca, Maria, and Salvà, Francesc

Subjects
DIARRHEA, TUMOR prevention, TUMOR treatment, THERAPEUTIC use of probiotics, MEDLINE, SYSTEMATIC reviews, GUT microbiome, PREBIOTICS
Abstract

What is known and objective: Cancer is one of the most important causes of morbidity and mortality worldwide. Pro‐, pre‐ and symbiotics can modulate host metabolism and gut microbiota and potentially help prevent cancer and modulate the adverse effects (AEs) of treatments. Numerous studies on this role for pro‐, pre‐ and symbiotics have reported inconsistent results. The purpose of this review was to examine current scientific evidence from randomized controlled trials (RCTs) on the effects of pro‐, pre‐ and symbiotics on the incidence of complications and AEs, especially diarrhoea, in cancer management. Methods: A systematic literature search was implemented in MEDLINE using the MeSH terms "probiotics", "prebiotics", "symbiotics" and "neoplasms", according to PRISMA guidelines. Reference lists were also handsearched to identify additional eligible RCTs. Three reviewers independently assessed the eligibility of each RCT. Of 714 retrieved abstracts, 22 articles with 2287 participants were included in the analysis. Results and discussion: The most studied bacteriotherapies were probiotics and symbiotics, in 10 and 7 studies, respectively. Both Lactobacillus and Bifidobacterium strains were used in 18 studies, while Lactobacillus and Bifidobacterium strains were individually used in 9 and 2 studies, respectively. Diarrhoea incidence rates were 3.2%‐39.1% in intervention groups and 6.7%‐60.9% in control groups, while infection incidence rates were 11.1%‐22.7% in intervention groups and 17.3%‐28.7% in control groups. What is new and conclusions: Pro‐, pre‐ and symbiotics may potentially be efficacious in reducing complications associated with chemotherapy, radiotherapy and surgery in patients with cancer. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. La riera d'Arenys, un patrimoni singular

Author

Forn i Salvà, Francesc

Abstract

Arenys de Munt té un patrimoni ric i força antic. Entre molts altres elements, destaquem per la seva antiguitat l’església de Sant Martí que ja arrossega quasi uns 500 anys d’existència, un forn de ceràmica a la zona de Can Jalpí del segle I de la nostra era i, com a cas ben excepcional, la nostra Riera, un patrimoni natural de més de 18000 anys formada, tal com la coneixem avui, de final del Dryas i començament de l’Holocè. Podria semblar que hauríem de tenir més cura i respecte cap al patrimoni més antic però, malauradament, no és així i aquest patrimoni tan valuós està patint un abandonament i una degradació sense precedents. Amb aquesta comunicació volem fer un petit homenatge a aquest patrimoni geològic singular per tal de posar en relleu, un cop més, la necessitat de valorar-lo i preservar-lo com cal.

Published
2018

23. La creació del poble modern. Arenys de Munt, segles XVI al XVIII

Author

Forn i Salvà, Francesc

Abstract

Al llarg dels segle XVI al XVIII Sant Martí d'Arenys, així com la majoria de pobles de la Marina del Vescomtat, va experimentar una evolució urbanística força singular que portà a la creació del poble tal com avui el coneixem. El poblament rural dispers, habitual en el segles medievals, fou substituït durant l'Edat Moderna per un poblament rural que hem anomenat semi concentrat que culminà, en ple segle XIX, en el poblament concentrat dels pobles actuals. Algun dels factors que influïren en aquesta evolució iniciada al segle XVI foren: la renovació dels edificis parroquials, la celebració de les bredes i l'empenta urbanísta del segle XVIII. Al mateix temps, es creava una nova identitat municipal que cristal·litzà a final del XVIII amb l'aparició de segells, escuts i símbols als diversos municipis.

Published
2017

25. Salutació

Author

Forn i Salvà, Francesc

Published
2016

27. Itinerarios de éxito y rupturas en la educación de segunda oportunidad

Author

Salvà, Francesc, Nadal, Juan, Melià Barceló, Maria Agnès, Salvà, Francesc, Nadal, Juan, and Melià Barceló, Maria Agnès

Abstract

(descriptivo): El concepto “educación de segunda oportunidad” (en adelante Esop) hace referencia a los dispositivos puestos en marcha para luchar contra la exclusión social de aquellas personas (en particular los jóvenes) que han abandonado los estudios con un nivel educativo inferior al de secundaria postobligatoria. Los programas de formación para el empleo dirigidos a jóvenes son los dispositivos de Esop más extendidos en España.En este artículo, se presentan los resultados de una investigación evaluativa de uno de estos programas basada en el método biográfico. El abordaje integral y la individualización, los contenidos de la formación y los aprendizajes realizados, las estrategias metodológicas, el vínculo afectivo y el entorno educativo se manifiestan como determinantes del éxito. También queda patente el impacto positivo de la participación a nivel personal y laboral.

Published
2016

29. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer

Author

Salvà, Francesc and Felip, Enriqueta

Subjects
Review Article
Abstract

Surgical resection followed by adjuvant chemotherapy is the standard of care for completely resected stages II and III non-small cell lung cancer (NSCLC) patients. In order to improve survival in patients with early-stage NSCLC, efforts have been focused on the use of chemotherapy and radiotherapy before surgery with the aim of reducing the risk of relapse. Neoadjuvant chemotherapy is an attractive treatment option which is employed in different tumors and may well be associated with certain advantages in NSCLC patients such as being effective in treating occult microscopic systemic disease, downstaging mediastinal lymph node and improving the success of surgery by tumor reduction. Furthermore, chemotherapy compliance prior to surgery is generally better than after surgery. The potential disadvantages are treatment-related toxicities and the delay of surgery. At present, neoadjuvant chemotherapy is still considered an experimental treatment modality in early-stage disease and its role should be more clearly defined.

Published
2013

35. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer

Author

Guillem Argiles, Giulia Martini, Emilia Sardo, Davide Ciardiello, Josep Tabernero, Nuria Mulet, Javier Ros, Francesc Salvà, Elena Elez, Iosune Baraibar, Jose Luis Cuadra, Ros, Javier, Baraibar, Iosune, Sardo, Emilia, Mulet, Nuria, Salvà, Francesc, Argilés, Guillem, Martini, Giulia, Ciardiello, Davide, Cuadra, José Lui, Tabernero, Josep, Élez, Elena, Institut Català de la Salut, [Ros J, Baraibar I, Salvà F, Argilés G, Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sardo E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mulet N] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medical Oncology, Institut Català d’Oncologia, Barcelona, Spain. [Martini G, Ciardiello D] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples, Caserta, Campania, Italy. [Tabernero J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. UVic-UCC, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
MAPK/ERK pathway, BRAF inhibitor, endocrine system diseases, Colorectal cancer, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], encorafenib, Review, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Còlon - Càncer - Tractament, chemistry.chemical_compound, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], Metàstasi, Encorafenib, Recte - Càncer - Tractament, Medicine, neoplasms, EGFR inhibitors, MEK inhibitor, business.industry, Kinase, BEACON clinical trial, BRAF V600E mutation, Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Binimetinib, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES], medicine.disease, digestive system diseases, BRAF V600E, EGFR inhibitor, Oncology, chemistry, colon cancer, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], binimetinib, Cancer research, business
Abstract

Inhibidor de BRAF; Binimetinib; Cáncer de colon BRAF inhibitor; Binimetinib; Colon cancer Inhibidor de BRAF; Binimetinib; Càncer de còlon Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling. BRAF mutations define a sub-population characterized by a poor prognosis and dismal median survival. Following successful outcomes with BRAF inhibition in BRAF mutant metastatic melanoma, this approach was evaluated in metastatic colorectal cancer (mCRC). The development and combination of targeted therapies against multiple signaling pathways has proved particularly successful, with improved survival and response rates. Areas covered: This review addresses the development of therapeutic strategies with inhibitors targeting MAPK/ERK and EGFR signaling in BRAF V600E mutated mCRC, focusing on encorafenib, binimetinib and cetuximab. A pharmacological and clinical review of these drugs and the therapeutic approaches behind their optimization are presented. Expert opinion: Exploiting knowledge of the mechanisms of resistance to BRAF inhibitors has been crucial to developing effective therapeutic strategies in BRAF-V600E mutant mCRC. The BEACON trial is a successful example of this approach, using encorafenib and cetuximab with or without binimetinib in patients with previously treated BRAF V600E mutant mCRC, showing an impressive improvement in clinical outcomes and tolerable toxicity compared with chemotherapy, establishing a new standard of care in this setting. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from Instituto de Salud Carlos III (ISCIII) FIS/FEDER (PI17/00947, PI20/00968) and from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 635342.

Published
2021

36. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer.

Author

Salvà F and Felip E

Abstract

Surgical resection followed by adjuvant chemotherapy is the standard of care for completely resected stages II and III non-small cell lung cancer (NSCLC) patients. In order to improve survival in patients with early-stage NSCLC, efforts have been focused on the use of chemotherapy and radiotherapy before surgery with the aim of reducing the risk of relapse. Neoadjuvant chemotherapy is an attractive treatment option which is employed in different tumors and may well be associated with certain advantages in NSCLC patients such as being effective in treating occult microscopic systemic disease, downstaging mediastinal lymph node and improving the success of surgery by tumor reduction. Furthermore, chemotherapy compliance prior to surgery is generally better than after surgery. The potential disadvantages are treatment-related toxicities and the delay of surgery. At present, neoadjuvant chemotherapy is still considered an experimental treatment modality in early-stage disease and its role should be more clearly defined.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results